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A Novel Ferrochelatase Gene Mutation (IVS12 A-C) in
Erythropoietic Protoporphyria
To the Editor:
Erythropoietic protoporphyria is known to be an autosomal
dominant inherited disorder with incomplete penetrance, with
few exceptions. Incomplete penetrance is explained by a combi-
nation of a mutant allele, a normal allele, and a low-expression
wild-type variant from molecular genetic studies (Gouya et al,
1999; 2002). The main characteristics of these patients are painful
cutaneous photosensitivity with elevated free erythrocyte proto-
porphyrin in erythrocytes. The molecular defects are known to
reside in the ferrochelatase gene, which is responsible for the ¢nal
step in the insertion of the ferrous iron in heme synthesis (Kra-
mer andViljoen, 1980). To date more than 65 mutations have been
reported in the ferrochelatase gene (Schneider-Yin et al, 2000).
A 23-y-old Korean male patient had experienced painful cuta-
neous photosensitivity from the age of 9 y. His father and grand-
mother also had a history of cutaneous photosensitivity. His free
erythrocyte protoporphyrin level in erythrocytes (2263.1 mg per
dl) was elevated, as were total bilirubin level in blood (1.9 mg
per dl) and urobilinogen in urine (2þ ). Routine blood, liver
function, and renal function tests were normal.
A blood sample (1ml) was collected in an ethylenediamine tet-
raacetic acid anticoagulation tube and extracted using a QIAamp
Blood Kit (Qiagen, Valencia, CA) to obtain the genomic DNA.
The ferrochelatase gene (11 exons including nearby introns) was
ampli¢ed with speci¢c primer sets that covered each exon
(Table I). PCR mixtures were initially treated for 10 min at
941C and then ampli¢ed for 30 cycles (30 s at 941C as a denatura-
tion step, 1 min at 56.41C (exons 1 and 9) or 601C (the other
exons) as an annealing step for the corresponding primer sets,
and 1 min at 721C as an elongation); ¢nally the PCR products
were treated for 10 min at 721C. The ampli¢ed PCR products
were puri¢ed using a High Pure PCR product puri¢cation kit
(Roche Diagnostics, Mannheim, Germany), and an ABI Prism
BigDye Terminator Cycle Sequencing Ready Reaction Kit v2.0
(Applied Biosystems, Foster City, CA) was used for the sequen-
cing reaction. The sequencing mixture (20 ml) included 8.0 ml of
Terminator Ready reaction mixture, 3 ng of ampli¢ed PCR pro-
duct DNA, and 3.2 pmol of each primer set. The mixtures were
ampli¢ed in a GeneAmp PCR System 9600 for 25 cycles (10 s at
961C, 5 s at 501C, and 4 min at 601C). The sequencing reaction
mixtures were puri¢ed by ethanol precipitation. The precipitated
samples were dissolved in 20 ml of formamide and denatured for 2
min at 951C, chilled on ice, and analyzed by electrophoresis in an
ABI Prism 310 Genetic Analyzer. The puri¢ed PCR products, in-
cluding the suspected single nucleotide polymorphism (SNP) or
mutation sites, were ampli¢ed with a newly synthesized geno-
typing primer (18 mer), which covered the 50 pre-SNP or premu-
tation site (50 -tgagactcttcttggacc-30 for A287T in exon 3 and
50 -gcactttaattttgtcac-30 for IVS12 A-C), for 25 cycles (10 s at
961C, 5 s at 501C, and 30 s at 601C) using a SNaPshot Multiplex
Kit (Applied Biosystems). The PCR products were puri¢ed and
then analyzed by electrophoresis in an ABI 3700 DNA analyzer
with Gene Scan software to ¢nd SNP or mutations. The PCR
products, which were ampli¢ed by the genomic DNA of the pa-
tient and the exon 2 primer set, were ligated into the vector using
pGEM-T vector kit (Promega, Madison, WI). The transformed
XL1-blue competent cell colonies by the cloned vector were cul-
tured in an LB plate containing ampicillin. The plasmid with the
correct insert size (480 bp) was veri¢ed by Pvu II and sequenced
using a DNA sequencing kit (ABI). A blood sample (1.5 ml) was
collected in an ethylenediamine tetraacetic acid anticoagulation
tube, extracted using a QIAamp RNA Blood Mini-kit (Qiagen),
and puri¢ed using a QIA shredder spin column (Qiagen) to ob-
tain total cellular RNA. RT-PCRwas performed by using a Qia-
gen One Step RT-PCR Kit and the primer set designed from
exon 1 and exon 4 (50 -gttcactcggcgcaaacat-30, 50 -gtgttggggga-
caattcatc-30). The reaction mixture was reverse transcribed
(30 min at 501C and 15 min at 941C) and ampli¢ed for 40 cycles
(1 min at 941C, 1 min at 521C, and 1 min at 721C). The RT-PCR
product was analyzed by 2% agarose gel electrophoresis and ethi-
dium bromide staining. Real-time PCRwas performed using a
High-Capacity cDNA Archive Kit and a TaqMan Universal
PCR Master Mix (ABI) with the gene-speci¢c Taqman probe
Table I. Primer pairs used for the ampli¢cation of the
corresponding 11 exons of the ferrochelatase gene
Primern Sequence (50-30) Annealing Temperture
Fc E1F ggagcgggcttctagctc 56.4
Fc E1R cctcagccctcccttctc
Fc E2F ccccttggagagggctta 60
Fc E2R aggatccagtggggaagg
Fc E3F ggaactggaggccacaga 60
Fc E3R gctctctccccctgcaat
Fc E4F cctcaagcttctgttttaaagg 60
Fc E4R caagggataacgcctgga
Fc E5F ccgtcagtgccataggaaa 60
Fc E5R ggccaataattcaagggaca
Fc E6F caggccatcttgtttttca 60
Fc E6R caagggaacagtaaggctca
Fc E7F ggcccccgaaactgttat 60
Fc E7R tgcactgggcttaggaca
Fc E8F ctgcggtgtttttctttgg 60
Fc E8R ccatggtcagcaatcagg
Fc E9F caaaatccattcaagcaggt 56.4
Fc E9R gaggacaccgtacatgcaaa
Fc E10F gccctgccccatgagtat 60
Fc E10R ttggggctatctgaaggaaa
Fc E11F caaagggctcaccactcg 60
Fc E11R gtcctgatggacattccaaa
nFc, ferrochelatase; E, exon; F, forward; R; reverse.
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(6FAM-cccagggtgcaaaacctcaagttcaac-TAMRA) and primers (50 -
ccacagaaacagcccagca-30, 50 -ccagttttcggcttcctcttc-30) that ampli¢ed
only the intact mRNAwith exon 2 because the probe and pri-
mers were designed to hybridize to the border area of exon 2 and
exon 3. Duplicate samples were reverse transcribed for 10 min at
251C and 2 h at 371C. This was followed by 40 rounds of ampli-
¢cation for 15 s at 951C and 1 min at 601C using the ABI
Prism 7700 sequence detection system (ABI). Quantitation of the
Figure1. Sequencing analysis of the junctional region of intron 1 and exon 2 of the ferrochelatase gene. (A) DNA sequences of the normal and
mutant alleles are shown by direct sequencing. (a) Normal DNA sequence. (b) The patient’s genomic DNA showed an IVS1^2 A/C heterozygote form
having the normal and mutant alleles. (B) DNA sequences of the intron 1exon 2 junctional region of the patient by pGEM-T cloning and single-strand
DNA sequencing. (a) IVS1^23 T (low-expression wild-type variant) and IVS1^2 A (wild-type) located on one strand and (b) IVS1^23 C (wild-type) and
IVS1^2 C (mutant) located on the other strand were detected.
Figure 2. Ferrochelatase mRNA expression in the peripheral blood leukocytes of the erythropoietic protopophyria patient. (A) Ethidium-
bromide-stained 2% agarose gel showing ferrochelatase RT-PCR product using primer sets covering exon 1 to exon 4. Alternative splicing was observed
in the patient due to skipping of exon 2. M, 100 bp DNA size marker; lane 1, erythropoietic protoporphyria patient (471 bp, 344 bp); lanes 2, 3, normal
controls (471 bp). (B) Quantitation of ferrochelatase mRNA containing the intact exon 2. The relative level of the patient’s ferrochelatase mRNA normal-
ized against the hARP mRNAwas 63% of the control level. The data are shown as the relative intensity (ferrochelatase/hARP mRNA) based on the mean
of duplicate samples.
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gene-speci¢c message levels was based on a comparison of the
£uorescence intensity in the unknown total RNA sample to the
£uorescence intensity from a standard curve of the control
mRNA levels. Ampli¢cation of the gene for the human acidic
ribosomal protein (hARP), which is a constitutively expressed
housekeeping gene, was performed on all samples tested to con-
trol for variations in the RNA amounts. The ferrochelatase
mRNA levels were subsequently normalized against the hARP
mRNA levels.
As a result of direct sequencing of 11 exons of ferrochelatase
genomic DNA using PCR primer sets synthesized to cover cor-
responding exons, we found several mismatching sequences com-
pared to the reference sequence (NT_011085) in the NCBI by Blast
search. Among them was a possible mutation site, which had the
potential to cause an abnormality of exon 2, such as an IVS1^2 A/C
heterozygote (acceptor splice site) in intron 1 (Fig 1A) and an
A287T(Q96R) homozygote in exon 3. Therefore, we analyzed
50 unrelated controls for similar base pair changes by using the
primer extension method or by direct sequencing. We detected
the A287T(Q96R) homozygote in all tested controls, but the
IVS1^2 A/C heterozygote or the IVS1^2 C/C homozygote was
not detected in any tested control (data not shown). Therefore,
the IVS1^2 A-C mutation is thought to be a novel mutation,
which was only detected in this patient. This acceptor splice site
mutation may cause exon skipping. Therefore, RT-PCR using
the primer set covering exon 2 was performed and an alternative
splicing band, which corresponded to the skipping of exon 2, was
found (Fig 2A). The skipped exon 2 in the 344 bp RT-PCR pro-
duct was veri¢ed by direct sequencing of the product (data not
shown). Real-time PCR of the ferrochelatase mRNA containing
the intact exon 2 using the Taqman technique revealed that the
patient’s ferrochelatase mRNA expression level was 63% of the
intensity of the control (Fig 2B). Because a relatively high level
of the intact ferrochelatase mRNA (63% of normal) with exon 2
was detected in this patient compared to the ferrochelatase activ-
ity (30%^40% of normal) of typical erythropoietic protopor-
phyria patients (Deybach, 2001), additional involvement of other
translational and/or post-translational interference in this patient
could be predicted to su⁄ciently decrease the ferrochelatase activ-
ity to generate cutaneous photosensitivity. To date, acceptor splice
mutation causing exon 2 skipping has been reported in IVS1^1
G-C mutation (Remenyik et al, 1998) and IVS2þ11A-G mu-
tation (Bloomer et al, 1998). This patient also had an IVS1^23 C/T
and an IVS3^48 C/T heterozygote form, which is a polymorph-
ism known to be related to a low-expression wild-type variant
(Gouya et al, 1999; 2002). pGEM-T cloning and sequencing of
exon 2 covering the IVS1^2 and IVS1^23 site performed to verify
the low-expression wild-type variant and the mutation were lo-
cated on di¡erent DNA strands. The IVS1^23 T (low-expression
wild-type variant) and IVS1^2 A (wild-type) located on one
strand and the IVS1^23 C (wild-type) and IVS1^2 C (mutant)
located on the other strand were detected (Fig 1B). Therefore,
the mutant allele causing exon 2 skipping and the low-expression
normal allele are believed to be responsible for generating the
phenotypic symptoms in this patient.
I herein report a novel mutation in the IVS1^2 A-C acceptor
splice site in the ferrochelatase gene in a patient with erythropoie-
tic protoporphyria.
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